产品描述
| Channel | Cav1.2/β2/α2/δ1, L-type |
| Catalog Ref. | ICE-CHO-Cav1.2 |
| Gene | CACNA1C |
| Sources | human |
| Expression system | CHO |
| Method | whole cell patch clamp |
| Reference Inhibitor | Nifedipine(31.3nM±6.8nM), verapamil |
| Target | Timothy syndrome, long QT syndrome, Pain, epilepsy, hypertension, stroke, arrhythmia, Autism |
| Channel | Cav2.2/β3/α2δ1 , N-type |
| Catalog Ref. | ICE-CHO-Cav2.2 |
| Gene | CACNA1B |
| Sources | human |
| Expression system | CHO |
| Method | whole cell patch clamp |
| Reference compound | Nifedipine, verapamil, Cadmium (IC50=7.0µm±704nM) |
| Target | Pain, Spinal cord injury, Kleefstra syndrome |
| Channel | CaV3.2, T-type |
| Catalog Ref. | ICE-CHO-Cav3.2 |
| Gene | CACNA1H |
| Sources | human |
| Expression system | HEK293 |
| Method | whole cell patch clamp |
| Reference compound | Nifedipine, verapamil, NiCl |
| Target | Convulsion |
| Channel | Cav2.1 |
| Catalog Ref. | ICE-CHO-Cav2.1 |
| Gene | CACNA1A |
| Sources | human |
| Expression system | CHO |
| Method | whole cell patch clamp |
| Reference inhibitor | Cadmium (2.9 ± 0.658µM) |
| Target | migraine, seizure and ataxia syndromes |
用户
新闻
应用
相关标准
相关药典
